Aprea Therapeutics Inc./$APRE
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aprea Therapeutics Inc.
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Ticker
$APRE
Sector
Primary listing
Employees
8
Headquarters
Website
APRE Metrics
BasicAdvanced
$10M
-
-$1.93
1.55
-
Price and volume
Market cap
$10M
Beta
1.55
52-week high
$2.22
52-week low
$0.55
Average daily volume
504K
Financial strength
Current ratio
5.629
Quick ratio
5.281
Profitability
EBITDA (TTM)
-13.212
Gross margin (TTM)
-2,364.68%
Net profit margin (TTM)
-4,409.16%
Operating margin (TTM)
-4,630.44%
Revenue per employee (TTM)
$40,000
Management effectiveness
Return on assets (TTM)
-41.45%
Return on equity (TTM)
-74.58%
Valuation
Price to revenue (TTM)
20.978
Price to book
0.6
Price to tangible book (TTM)
0.6
Price to free cash flow (TTM)
-0.465
Free cash flow yield (TTM)
-215.10%
Free cash flow per share (TTM)
-1.972
Growth
Revenue change (TTM)
-80.98%
Earnings per share change (TTM)
-18.07%
3-year earnings per share growth (CAGR)
-69.51%
APRE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aprea Therapeutics Inc. stock?
Aprea Therapeutics Inc. (APRE) has a market cap of $10M as of April 13, 2026.
What is the P/E ratio for Aprea Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aprea Therapeutics Inc. (APRE) stock is 0 as of April 13, 2026.
Does Aprea Therapeutics Inc. stock pay dividends?
No, Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders as of April 13, 2026.
When is the next Aprea Therapeutics Inc. dividend payment date?
Aprea Therapeutics Inc. (APRE) stock does not pay dividends to its shareholders.
What is the beta indicator for Aprea Therapeutics Inc.?
Aprea Therapeutics Inc. (APRE) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.